» Articles » PMID: 28694043

Risk Factors and Clinical Characteristics of Non-promyelocytic Acute Myeloid Leukemia of Intracerebral Hemorrhage: A Single Center Study in China

Overview
Journal J Clin Neurosci
Specialty Neurology
Date 2017 Jul 12
PMID 28694043
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although high mortality in patients with acute leukemia (AL) is associated with intracranial hemorrhage (ICH), the clinical features and pathogenesis of AL patients with cerebral hemorrhage are not well known.

Methods: We diagnosed 90 patients with ICH from a total of 1467 patients with non-promyelocytic AL who had been hospitalized in the First Affiliated Hospital of Medical School of Zhejiang University from January 2010 to October 2015. Moreover, the risk factors of ICH death were evaluated.

Result: Median age at ICH was 51years old, in which men accounted for 52.2%. They also accounted for 85.6% of acute myeloid leukemia. The relative incidence of ICH was the highest in M2 and M5 (60.1%). ICH presented with higher peripheral blood white blood cell count (WBC) (P<0.001), lower peripheral platelet counts (P<0.001), lower albumin (P<0.001), lower fibrous protein (P<0.001) and prolongation of prothrombin time (P<0.001) compared to those observed in the patients of NICH group; multivariate analysis, independent risk factors for death in patients with ICH include: WBC≥30.00×109/l and prothrombin time≥12.91 s.

Conclusions: Leukocytosis and coagulation dysfunctions might be the main pathogenesis of acute leukemia complicated with cerebral hemorrhage.

Citing Articles

Clinical features and risk factors of HIV-infected patients with intracerebral hemorrhage: a retrospective study with propensity score matching analysis.

Huang Q, Chen S, Huang H, Deng X, Cen G, Wang M Front Cell Infect Microbiol. 2025; 14():1498327.

PMID: 39839258 PMC: 11746895. DOI: 10.3389/fcimb.2024.1498327.


Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect.

Perrone S, Imperatore S, Sucato G, Notarianni E, Corbingi A, Andriola C Ann Hematol. 2023; 102(11):3025-3030.

PMID: 37606693 PMC: 10567884. DOI: 10.1007/s00277-023-05392-2.


Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer.

Cui H, Ren X, Dai L, Chang L, Liu D, Zhai Z Front Immunol. 2023; 14:1145552.

PMID: 36969219 PMC: 10031006. DOI: 10.3389/fimmu.2023.1145552.


Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience.

Koschade S, Stratmann J, Zeiner P, Finkelmeier F, Chromik J, Steffen B Ann Hematol. 2023; 102(5):1045-1052.

PMID: 36947211 PMC: 10102131. DOI: 10.1007/s00277-023-05178-6.


Intraparenchymal Hemorrhage: A Fatal Presentation of Undiagnosed Acute Myelogenous Leukemia.

Hamadi R, Assaad M, Zurndorfer J, El Gharib K, Kwok R, Dhar M Cureus. 2022; 14(6):e25592.

PMID: 35795513 PMC: 9250100. DOI: 10.7759/cureus.25592.